Market Overview

UPDATE: Citigroup Raises PT on Stryker Following Mixed 2Q13 Results

Share:
Related SYK
Benzinga's Top Upgrades
Earnings Scheduled For October 27, 2016
Three 10%+ Dividend Increases Among 11 Announcements Expected For December (Seeking Alpha)

In a report published Monday, Citigroup analyst Matthew J. Dodds reiterated a Neutral rating on Stryker (NYSE: SYK), and raised the price target from $72.00 to $78.00.

In the report, Citigroup noted, “SYK had a good quarter, but missed consensus EPS and had to lower 2013 guidance due entirely to FX. SYK is now implementing a hedging program to minimize future risk, but it's arriving too late to provide cover in 2013. Sales of $2.21B (+5.1%) were roughly $15MM ahead of the Street and inline with our forecast. Excluding FX (-150bp), acquisitions (+60bp) and an extra selling day (+150bp), organic sales growth was 4.4% which should still be north of the peer group. Hips (+6% cc), Knees (+5% cc), and Trauma/Extremities (+17% cc) were all ahead of the Street and point to share gains as most competitors appeared to also have an extra selling day. SYK did better than expected in Medical (+10% cc) and appeared to gain share in Spine (+4% cc).”

Stryker closed on Friday at $70.88.

Latest Ratings for SYK

DateFirmActionFromTo
Nov 2016BMO CapitalUpgradesUnderperformMarket Perform
Oct 2016SunTrust Robinson HumphreyInitiates Coverage OnBuy
Jun 2016GuggenheimInitiates Coverage onBuy

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Citigroup Matthew J. DoddsAnalyst Color Price Target Analyst Ratings

 

Related Articles (SYK)

View Comments and Join the Discussion!